Digestive Diseases and Sciences

, Volume 39, Issue 2, pp 393–401 | Cite as

Recombinant human epidermal growth factor prevents sclerotherapy-induced esophageal ulcer and stricture formations in pigs

  • Claus Orloff Juhl
  • Lone Susanne Jensen
  • Torben Steiniche
  • Effat Moussa
Originals Articles

Abstract

Human epidermal growth factor (EGF), a naturally occurring protein, has been implicated in the protection of gastrointestinal mucosal integrity. The efficacy of EGF in the prevention of sclerotherapy-induced esophageal lesions was investigated in 18 minipigs with surgically induced portal hypertension. The animals underwent five weekly sessions of sclerotherapy with polidocanol 2% and were concomitantly treated with either placebo or EGF administered either paravenously or subcutaneously. EGF significantly (P<0.05) reduced esophageal ulcerations, stricture formations, and mucosal histological damage associated with sclerotherapy. The drug was well-tolerated with no overt toxicity. These results suggest a potentially important clinical value of EGF as an adjunctive treatment with the sclerotherapy.

Key words

esophageal varices Aethoxysclerol portal hypertension sclerotherapy urogastrone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Paquet K-J, Feussner H: Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophagogastic varices: A prospective controlled randomized trial. Hepatology 5:580–583, 1985Google Scholar
  2. 2.
    Westaby D, Hayes PC, Gimson AES, Polson RJ, Williams R: Controlled clinical trial of injection sclerotherapy for active variceal bleeding. Hepatology 9:274–277, 1989Google Scholar
  3. 3.
    Sørensen TIA: Sclerotherapy after first variceal hemorrhage in cirrhosis: A randomized multicenter trial. N Engl J Med 311:1594–1600, 1984Google Scholar
  4. 4.
    Westaby D, Macdougall BRD, Williams R: Improved survival following injection sclerotherapy for esophageal varices: Final analysis of a controlled trial. Hepatology 5:827–830, 1985Google Scholar
  5. 5.
    Korula J, Balart LA, Radvan G, Zweiban BE, Larson AW, Kao HW, Yamada S: A prospective, randomized controlled trial of chronic esophageal variceal sclerotherapy. Hepatology 5:584–589, 1985Google Scholar
  6. 6.
    Koch H, Henning H, Grimm H, Soehendra N: Prophylactic sclerosing of esophageal varices—results of a prospective controlled study. Endoscopy 18:40–43, 1986Google Scholar
  7. 7.
    Gregory PB: Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. N Engl J Med 324:1779–1784, 1991Google Scholar
  8. 8.
    Sanowski RA, Waring JP: Endoscopic techniques and complications in variceal sclerotherapy. J Clin Gastroenterol 9:504–513, 1987Google Scholar
  9. 9.
    Sørensen TIA, Burcharth F, Pedersen ML, Findahl F: Oesophageal stricture and dysphagia after endoscopic sclerotherapy for bleeding varices. Gut 25:473–477, 1984Google Scholar
  10. 10.
    Singai AK, Sarin SK, Misra SP, Broor SL: Ulceration after esophageal and gastric variceal sclerotherapy—influence of sucralfate and other factors on healing. Endoscopy 20:238–240, 1988Google Scholar
  11. 11.
    Snady H, Rosman AS, Korsten MA: Prevention of stricture formation after endoscopic sclerotherapy of esophageal varices. Gastrointest Endosc 35:377–380, 1989Google Scholar
  12. 12.
    Reilly JJ, Schade RR, Van Thiel DS: Esophageal function after injection sclerotherapy: Pathogenesis of esophageal stricture. Am J Surg 147:85–88, 1984Google Scholar
  13. 13.
    Sarin SK, Nanda R, Vij JC, Anand BS: Oesophageal ulceration after sclerotherapy—a complication or an accompaniment? Endoscopy 18:44–45, 1986Google Scholar
  14. 14.
    Iso Y, Kitano S, Iwanaga T, Koyanagi N, Sugimachi K: A prospective randomized study comparing the effects of large and small volumes of the sclerosant 5% ethanolamine oleate injected into esophageal varices. Endoscopy 20:285–288, 1988Google Scholar
  15. 15.
    Tabibian N, Smith JL, Graham DY: Sclerotherapy-associated esophageal ulcers: Lessons from a double-blind, randomized comparison of sucralfate suspension versus placebo. Gastrointest Endosc 35:312–315, 1989Google Scholar
  16. 16.
    Paquet KJ, Koussouris P, Keinath R, Rambach W, Kalk J-F: A comparison of sucralfate with placebo in the treatment of esophageal ulcers following therapeutic endoscopic sclerotherapy of esophageal varices—a prospective controlled randomized trial. Am J Med 91:S147-S150, 1991Google Scholar
  17. 17.
    Pulanic R, Vrhovac B, Jokic N, Rosandic-Pilas M, Salamon V, Opacic M, Rustemovic N, Korac B, Vucelic B: Prophylactic administration of ranitidine after sclerotherapy of esophageal varices. Int J Clin Pharmacol Ther Toxicol 29:347–351, 1991Google Scholar
  18. 18.
    Johlin FC, Labrecque DR, Neil GA: Omeprazole heals mucosal ulcers associated with endoscopic injection sclerotherapy. Dig Dis Sci 37:1373–1376, 1992Google Scholar
  19. 19.
    Marti U, Burwen SJ, Jones AL: Biological effects of epidermal growth factor, with emphasis on the gastrointestinal tract and liver: An update. Hepatology 9:126–138, 1989Google Scholar
  20. 20.
    Olsen PS: Role of epidermal growth factor in gastroduodenal mucosal protection. J Clin Gastroenterol 10:S146-S151, 1988Google Scholar
  21. 21.
    Jensen LS, Krarup N, Larsen JA, Juhl C, Nielsen TH, Dybdahl H: Chronic portal venous hypertension. The effect on liver blood flow and liver function and the development of esophageal varices. Scand J Gastroenterol 22:463–470, 1987Google Scholar
  22. 22.
    Jensen LS, Krarup N, Larsen JA, Juhl C, Nielsen TH, Dybdahl H: Effect of endoscopic sclerotherapy of esophageal varices on liver blood flow and liver function. Scand J Gastroenterol 22:619–626, 1987Google Scholar
  23. 23.
    Weibel ER: Sterological Methods. Practical Methods for Biological Morphometry. New York, Academic Press, 1980Google Scholar
  24. 24.
    Conorer WJ: Practical Non-Parametric Statistics. New York, John Wiley & sons, 1980Google Scholar
  25. 25.
    Winer BJ: Statistical Principals in Experimental Design. New York: McGraw-Hill, 1971Google Scholar
  26. 26.
    Bazozowski T, Majka J, Garlicki J, Orozoqwicz D, Konturek SJ: Role of polyamines and prostaglandins in gastroprotective action of epidermal growth factor against ethanol injury. J Clin Gastroenterol 13:S98-S102, 1991Google Scholar
  27. 27.
    Amagase H, Murakami T, Misaki M, Higashi Y, Ushijima M, Fuwa T, Yata N: Protective effect of human epidermal growth factor against the experimental gastric mucosal lesions in rats. Life Sci 47:1031–1031, 1990Google Scholar
  28. 28.
    Sandweiss DJ, Saltzstein HC, Farbman A: The prevention of healing of experimental peptic ulcer in Mann-Williamson dogs with the anterior pituitary-like hormone (Antuitrin-S). A preliminary report. Am J Dig Dis 5:24–30, 1938Google Scholar
  29. 29.
    Sandweiss DJ: The immunizing effect of the anti-ulcer factor in normal human urine (Anthelone) against the experimental gastrojejunal (peptic) ulcer in dogs. Gastroenterology 1:965–969, 1943Google Scholar
  30. 30.
    Sauerbruch T, Wirsching R, Holl J, Grobl J, Weinzierl M: Effects of repeated injection sclerotherapy on acid gastroesophageal reflux. Gastrointest Endosc 32:81–83, 1986Google Scholar
  31. 31.
    Waring JP, Talbert GA, Austin J, Sanowski RA: Gastroesophageal reflux and sclerotherapy strictures. Am Surg 56:662–664, 1990Google Scholar
  32. 32.
    Banks-Schlegel SP, Quintero J: Human esophageal carcinoma cells have fewer, but higher affinity epidermal growth factor receptors. J Biol Chem 261:4359–4362, 1986Google Scholar
  33. 33.
    Lembach KJ: Enhanced synthesis and extracellular accumulation of hyaluronic acid during stimulation of quiescent human fibroblasts by mouse epidermal growth factor. J Cell Physiol 89:277–288, 1976Google Scholar
  34. 34.
    Chen LB, Gudor RC, Sun T-T, Chen AB, Mosesson MW: Control of a cell surface major glucoprotein by epidermal growth factor. Science 197:776–778, 1977Google Scholar
  35. 35.
    Bockus BJ, Stiles CD: Regulation of cytoskeletal architecture by platelet-derived growth factor, insulin and epidermal growth factor. Exp Cell Res 153:186–197, 1984Google Scholar
  36. 36.
    Sumi S, Inoue K, Hosotani R, Kogire M, Doi R, Yun M, Higashide S, Minote H, Takaori K, Kaji H, Uchida K, Tobe T: Effect of human epidermal growth factor (hEGF) on splanchnic circulation in dogs. Life Sci 47:1115–1119, 1990Google Scholar
  37. 37.
    Juhl CO, Jensen LS, Mulvany MJ: Time course of development of changes in the structure and reactivity of small veins from portal hypertensive rabbits. Clin Sci 77:205–211, 1989Google Scholar
  38. 38.
    Matsuo Y, Gotoh Y, Itoh M, Asaki S, Sugiyama M, Ohshiba S, Nagataki S, Hayakawa A, Ogawa N, Urakawa M, Yamazaki W: Randomized, double-blind comparison of epidermal growth factor from human urine (MG III) with the active placebo in treatment of gastric ulcers. An abstract presented at the First United European Gastroenterology Week, Athens, Greece, 1992Google Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • Claus Orloff Juhl
    • 2
    • 1
  • Lone Susanne Jensen
    • 2
    • 1
  • Torben Steiniche
    • 2
    • 1
  • Effat Moussa
    • 2
    • 1
  1. 1.Department of PathologyAarhus County HospitalAarhusDenmark
  2. 2.Institute of Experimental Clinical ResearchUniversity of AarhusAarhus CDenmark

Personalised recommendations